

**Date:** June 27, 2024

**To,**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> floor, Dalal Street,  
Mumbai – 400 001,  
Maharashtra, India.

**Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended (“SEBI LODR”) for the draft Scheme of Amalgamation amongst Medinova Diagnostic Services Limited (the “Transferor Company” or the “Company”) and Vijaya Diagnostic Centre Limited (the “Transferee Company”) and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (the “Scheme”)**

**Company's Scrip Code in BSE** : 526301  
**ISIN** : INE047C01019

The Board of Directors of the Company at their meeting held on June 26, 2024, have considered and approved the Scheme for inter alia the amalgamation of the Transferor Company into and with the Transferee Company on a going concern basis, subject to the approval of the shareholders, creditors of the Company and the Transferor Company (unless the same are dispensed with), the Stock Exchange(s)/ Securities and Exchange Board of India (“SEBI”), National Company Law Tribunal, Hyderabad Bench (“NCLT”) and other necessary approval, consents, permission and sanction of relevant statutory and regulatory authorities.

The equity shares of the Company are listed on BSE Limited.

As per the provisions of Regulation 37 of SEBI LODR Regulations, a listed entity desirous of undertaking a Scheme of Amalgamation shall file the draft scheme of amalgamation, proposed to be filed before any Court or Tribunal under Sections 230 to 232 of Companies Act, 2013, whichever applicable (along with a non-refundable fee as specified) with the stock exchange(s) for obtaining the Observation Letter or No-objection letter, before filing such scheme with any Court or Tribunal, in terms of requirements specified by SEBI or stock exchange(s) from time to time.

In accordance with Paragraph 1 of Part I (A) of the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 issued by SEBI titled ‘*Master Circular on (i) Scheme of arrangement by Listed Entities and (ii) Relaxation under Sub-Rule (7) of rule 19 of the Securities Contracts (Regulation) Rules, 1957 (“SEBI Master Circular”)*’, the Board of Directors of the Company has chosen BSE Limited (“BSE”) as its ‘Designated Stock Exchange’ (“DSE”) for coordination with SEBI.

Pursuant to the SEBI Master Circular, the checklist(s) published by BSE Limited and Regulation 37 of SEBI LODR Regulations, we hereby provide the required documents/information, as more particularly mentioned/ referred in the ‘Index of Documents Submitted’ enclosed herewith, duly initialed by the Company Secretary and/ or Compliance Officer of the Company for your kind perusal.


On the basis of the above submissions, we request you to kindly consider this application seeking the No-objection from your good office and grant your approval and consent to the Scheme at your earliest convenience.

**Regd. Office:** H. No. 7-1-58, Unit No. 1 / Flat No. 301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad – 500016, Telangana, India, Phone- 040 - 42604250, E-mail- medicorp@medinovaindia.com, Website- www.medinovaindia.com



Should you require any further information/ clarification on the Scheme, we shall be glad to provide the same.

**Thanking you.**  
**Yours sincerely,**  
**For and on behalf of Medinova Diagnostic Services Limited**

  
\_\_\_\_\_  
**Hansraj Singh**  
**Company Secretary**  
**M. No. F11438**  
**Place: Hyderabad**  
**Date: June 27, 2024**

